606 related articles for article (PubMed ID: 24471924)
1. Current strategies for treatment of relapsed/refractory multiple myeloma.
Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
[TBL] [Abstract][Full Text] [Related]
2. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
4. [Management of multiple myeloma in the relapsed/refractory patient].
Tabayashi T
Rinsho Ketsueki; 2019; 60(9):1257-1264. PubMed ID: 31597851
[TBL] [Abstract][Full Text] [Related]
5. How is patient care for multiple myeloma advancing?
Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A
Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554
[TBL] [Abstract][Full Text] [Related]
6. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
Nijhof IS; van de Donk NWCJ; Zweegman S; Lokhorst HM
Drugs; 2018 Jan; 78(1):19-37. PubMed ID: 29188449
[TBL] [Abstract][Full Text] [Related]
7. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
8. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
Moreau P
Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
Moreau P
Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
[TBL] [Abstract][Full Text] [Related]
10. [Current treatment of refractory and relapsed multiple myeloma].
Sasaki M
Rinsho Ketsueki; 2016; 57(10):2084-2095. PubMed ID: 27795518
[TBL] [Abstract][Full Text] [Related]
11. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
12. Future agents and treatment directions in multiple myeloma.
Ocio EM; Mitsiades CS; Orlowski RZ; Anderson KC
Expert Rev Hematol; 2014 Feb; 7(1):127-41. PubMed ID: 24350987
[TBL] [Abstract][Full Text] [Related]
13. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
van de Donk NW; Lokhorst HM
Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
[TBL] [Abstract][Full Text] [Related]
14. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Boudreault JS; Touzeau C; Moreau P
Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
[TBL] [Abstract][Full Text] [Related]
15. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Dimopoulos MA; Richardson P; Lonial S
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):460-473. PubMed ID: 35148975
[TBL] [Abstract][Full Text] [Related]
16. [Treatment strategy for relapsed or refractory myeloma according to the new Guidelines].
Ozaki S
Rinsho Ketsueki; 2018; 59(10):2178-2188. PubMed ID: 30305524
[TBL] [Abstract][Full Text] [Related]
17. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
Varga C; Laubach JP; Anderson KC; Richardson PG
Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Moreau P; de Wit E
Br J Haematol; 2017 Oct; 179(2):198-218. PubMed ID: 28556890
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
[TBL] [Abstract][Full Text] [Related]
20. Management of relapsed multiple myeloma after autologous stem cell transplant.
Holstein SA; Richardson PG; Laubach JP; McCarthy PL
Biol Blood Marrow Transplant; 2015 May; 21(5):793-8. PubMed ID: 25652690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
